Citation Impact
Citing Papers
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
2002
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Functional diversity of helper T lymphocytes
1996 StandoutNature
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
2001
Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome)
1997
Amyloidosis
1994
PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
1999
MYC on the Path to Cancer
2012 Standout
The Systemic Amyloidoses
1997 Standout
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
2008 StandoutNature
Clinical translation of angiogenesis inhibitors
2002 Standout
A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)
2002
High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.
1994
NF-κB in cancer: from innocent bystander to major culprit
2002 Standout
Tumor angiogenesis: past, present and the near future
2000
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
2012
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA
1999
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Angiogenesis in cancer and other diseases
2000 StandoutNature
The biology of VEGF and its receptors
2003 Standout
Neurogenesis in the adult human hippocampus
1998 Standout
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
2013
Cyclins and oncogenesis
1993
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
Cancer genes and the pathways they control
2004 Standout
Current Therapy for Multiple Myeloma
2002
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
2009
Protein folding and misfolding
2003 StandoutNature
Angiogenesis-dependent diseases
2001
Immunity, Inflammation, and Cancer
2010 Standout
Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica
1994
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
2003
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
2001
Genetic events in the pathogenesis of multiple myeloma
2007
Systemic amyloidosis
2015 Standout
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment
2004 Standout
High Serum Lactate Dehydrogenase Level as a Marker for Drug Resistance and Short Survival in Multiple Myeloma
1991
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
1997
Thalidomide in the Treatment of Relapsed Multiple Myeloma
2000
Capturing complex 3D tissue physiology in vitro
2006 Standout
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
2008
Metastasis to bone: causes, consequences and therapeutic opportunities
2002 Standout
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials
2001
Multiple myeloma: evolving genetic events and host interactions
2002
Polymyalgia Rheumatica and Giant-Cell Arteritis
2002 Standout
A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine
1997
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
2002 Standout
Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity
1990
Mechanisms of Bone Metastasis
2004 Standout
A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis
1995 Standout
Grand Rounds - Hammersmith Hospital: Cardiac transplantation for AL amyloidosis
1994
Eosinophils: Biology and Role in Disease
1995
High-risk multiple myeloma treated with high-dose melphalan.
1992
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma
1997
Immunofluorescence Labeling Indices in Myeloma and Related Monoclonal Gammopathies
1987
Pro-angiogenic Activities of CYR61 (CCN1) Mediated through Integrins αvβ3 and α6β1 in Human Umbilical Vein Endothelial Cells
2002 Standout
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
1993 StandoutNature
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Molecular Mechanisms of Amyloidosis
2003 Standout
Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only
1996
Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma
1992 Standout
Tumorigenesis and the angiogenic switch
2003 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement and relation to survival
1985
Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins.
1988
High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement [letter]
1996
Angiogenesis Research: Guidelines for Translation to Clinical Application
2001
Amyloidosis of the AL type
1979
Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies
1994
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
2006
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 Standout
Normal and abnormal aspects of proteinuria
1986
Identification of CD68+lin− Peripheral Blood Cells with Dendritic Precursor Characteristics
1998
Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part I: Historical perspectives, histochemical methods and cell kinetics
1995
New drug therapy of amyloidoses: resorption of AL-type deposits with 4'- iodo-4'-deoxydoxorubicin
1995
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
2004
Amyloid Deposits and Amyloidosis
1980 Standout
Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis
2013
Infusion of Light Chains From Patients With Cardiac Amyloidosis Causes Diastolic Dysfunction in Isolated Mouse Hearts
2001
Multiple Myeloma
2010
Effect of Dose-Intensive Intravenous Melphalan and Autologous Blood Stem-Cell Transplantation on AL Amyloidosis–Associated Renal Disease
2001
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
2005
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
1999
Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma
1997
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
1998
Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay
2010
A novel membrane antigen selectively expressed on terminally differentiated human B cells
1994
Genetics and Cytogenetics of Multiple Myeloma
2004
Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma
1996
Plasmablastic Morphology—An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group
1998
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
2006
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
Increased Frequency of Surface IgA-Positive Plasma Cells in the Intestinal Lamina Propria and Decreased IgA Excretion in Hyper IgA (HIGA) Mice, a Murine Model of IgA Nephropathy with Hyperserum IgA
2000 StandoutNobel
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)
2011
Enhancement of human basophil histamine release by interleukin 5.
1990
Immunobiology of Dendritic Cells
2000 Standout
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Diverse karyotypic abnormalities of the c -myc locus associated with c -myc dysregulation and tumor progression in multiple myeloma
2000
High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma
1994
Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry
1990
Multiple Myeloma
2011 Standout
Evidence That Amyloidogenic Light Chains Undergo Antigen-Driven Selection
1998
Genes Expressed in Human Tumor Endothelium
2000 StandoutScience
Heart transplantation in AL amyloidosis
1995
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
1995
International Staging System for Multiple Myeloma
2005 Standout
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
2006
Autocrine/Paracrine Mechanisms in Human Hematopoiesis
2001
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of PR Greipp being referenced
Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
1999
Multiple myeloma: circulating lymphocytes that express plasma cell antigens
1984
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis
1985
Response rates and survival in primary systemic amyloidosis
1991
Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo
1978
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
The plasma cell labeling index: a valuable tool in primary systemic amyloidosis
1989
Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma.
1995
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling index.
1991
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases
1986
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis
1985
Multiple myeloma: significance of plasmablastic subtype in morphological classification
1985
Localization of eosinophil granule major basic protein in human basophils.
1983
Advances in the diagnosis and management of myeloma.
1992
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma
1988
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma
1988
Multiple myeloma: significance of plasmablastic subtype in morphological classification
1985
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis
2009
Response rates and survival in primary systemic amyloidosis
1991
Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma
1983
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases
1986